SEC Form SC 13G/A filed by Legend Biotech Corporation (Amendment)

2/9/24 9:16:05 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $LEGN alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.2 LEGEND BIOTECH CORP COMMON STOCK Cusip #52490G102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #52490G102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 25,582,794 Item 6: 0 Item 7: 25,595,988 Item 8: 0 Item 9: 25,595,988 Item 11: 7.040% Item 12: HC Cusip #52490G102 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 25,595,988 Item 8: 0 Item 9: 25,595,988 Item 11: 7.040% Item 12: IN Item 1(a). Name of Issuer: LEGEND BIOTECH CORP Item 1(b). Address of Issuer's Principal Executive Offices: 2101 COTTONTAIL LANE SOMERSET, NJ 08873 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 52490G102 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 25,595,988 (b) Percent of Class: 7.040% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 25,595,988 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of LEGEND BIOTECH CORP. No one other person's interest in the COMMON STOCK of LEGEND BIOTECH CORP is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research (Japan) Limited IA Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of LEGEND BIOTECH CORP at December 29, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $LEGN alert in real time by email

Recent Analyst Ratings for

$LEGN

Date	Price Target	Rating	Analyst
10/8/2024	$86.00	Buy	Redburn Atlantic
6/17/2024	$88.00	Buy	Truist
5/24/2024	$86.00 → $73.00	Buy	H.C. Wainwright
5/23/2024	$60.00	Buy	Deutsche Bank
4/17/2024	$65.00	Sector Perform → Sector Outperform	Scotiabank
4/3/2024	$82.00	Overweight	Cantor Fitzgerald
3/13/2024	$86.00	Outperform	Raymond James
12/19/2023		Sector Perform	Scotiabank

More analyst ratings

SEC Form SC 13G/A filed by Legend Biotech Corporation (Amendment)

Chat with this insight

Recent Analyst Ratings for
$LEGN

$LEGN
Market Insights

Live Market Insights

Warner Bros. Discovery & Coinbase Are Among 10 Large Cap Stocks That Shined Most Last Week (July 14-July 20): Are The Others In Your Portfolio?

Scotiabank Maintains Sector Outperform on Legend Biotech, Raises Price Target to $70

Cintas Posts Upbeat Earnings, Joins CommScope Holding, Virtu Financial And Other Big Stocks Moving Higher On Thursday

$LEGN
Financials

Live finance-specific insights

Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights

Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024

$LEGN
Leadership Updates

Live Leadership Updates

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors

$LEGN
Press Releases

Fastest customizable press release news feed in the world

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results

$LEGN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Redburn Atlantic initiated coverage on Legend Biotech with a new price target

Truist initiated coverage on Legend Biotech with a new price target

H.C. Wainwright reiterated coverage on Legend Biotech with a new price target

$LEGN
SEC Filings

SEC Form 6-K filed by Legend Biotech Corporation

SEC Form 6-K filed by Legend Biotech Corporation

SEC Form 6-K filed by Legend Biotech Corporation

$LEGN
Large Ownership Changes

This live feed shows all institutional transactions in real time.